Relmada Therapeutics (RLMD) EBIT (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of EBIT data on file, last reported at -$19.5 million in Q1 2026.

• On a quarterly basis, EBIT fell 6.82% year-over-year to -$19.5 million in Q1 2026; TTM through Mar 2026 was -$60.3 million, a 23.73% increase from a year earlier, with the FY2025 full-year figure at -$59.1 million, up 29.55% from the prior year.
• EBIT for Q1 2026 stood at -$19.5 million, up from -$20.3 million in the prior quarter.
• Over the last five years, EBIT for RLMD reached as high as -$10.2 million in Q2 2025 and fell as low as -$45.5 million in Q2 2022.
• Historically, EBIT has averaged -$25.1 million across 5 years, with a median of -$23.0 million in 2024.
• Across the five-year window, EBIT tumbled 71.99% in 2022 and soared 55.12% in 2025, its largest moves.
• Year by year, EBIT stood at -$38.7 million in 2022, then surged by 30.68% to -$26.8 million in 2023, then increased by 28.9% to -$19.1 million in 2024, then retreated by 6.59% to -$20.3 million in 2025, then rose by 4.29% to -$19.5 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$19.5 million in Q1 2026, -$20.3 million in Q4 2025, and -$10.3 million in Q3 2025.